Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Zynex ( (ZYXIQ) ).
On February 17, 2026, Zynex entered into a non-prosecution agreement with the U.S. Attorney’s Office for the District of Rhode Island, resolving a federal investigation into health care and securities fraud-related conduct under prior management between 2017 and August 2025. The deal, which is subject to bankruptcy court approval, requires Zynex to admit criminal law violations tied to former executives, pay a performance-linked criminal penalty of $5 million to $12.5 million, forfeit roughly $98 million in previously billed but unpaid claims, and maintain extensive cooperation, governance, and compliance obligations through at least 2034.
The company, which filed for Chapter 11 protection on December 15, 2025, has implemented sweeping remediation measures since new management arrived in August 2025, including redesigned supply replenishment, stricter billing aligned with payor rules, and on-label marketing that meets FDA expectations. Zynex says the resolution removes the threat of prosecution and an independent monitor, helping clear a major legal overhang as it pursues a near-term emergence from Chapter 11, though it warns that trading in its securities remains highly speculative and that equity holders face a significant risk of loss in the restructuring.
The most recent analyst rating on (ZYXIQ) stock is a Hold with a $0.05 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXIQ Stock Forecast page.
Spark’s Take on ZYXIQ Stock
According to Spark, TipRanks’ AI Analyst, ZYXIQ is a Underperform.
The score is driven primarily by distressed financial performance (declining revenue, losses, negative equity/leverage risk) and strongly bearish technicals (price far below moving averages and negative MACD). Valuation is not meaningfully supportive due to negative earnings and no dividend, while the earnings call outlines remediation efforts but confirms significant ongoing financial strain.
To see Spark’s full report on ZYXIQ stock, click here.
More about Zynex
Zynex, Inc., founded in 1996 and based in Englewood, Colorado, is a pain management device manufacturer and distributor focused on durable medical equipment. The company provides highly effective products for patients and payors, and in recent months new management has emphasized compliance‑by‑design, overhauling order-to-cash processes and tightening billing, marketing and operational controls.
Average Trading Volume: 6,180,779
Technical Sentiment Signal: Sell
Current Market Cap: $1.22M
For a thorough assessment of ZYXIQ stock, go to TipRanks’ Stock Analysis page.